Stop
Targeting ACC1 as a novel therapeutic for the treatment of breast cancer
Published: 10/10/19 12:21 AM
New and improved treatment
Associate Professor
Matthew Naylor
Altered metabolism is a key feature of cancer, with metabolic pathways reprogramed to meet the energy demands of cancer cell growth. However, little is known about the role of increased lipid metabolism in breast cancer. We now show that ACC1, a key regulator of lipid metabolism, is expressed by breast tumours, and that inhibiting ACC1 impairs breast cancer progression. This proposal will validate and characterise ACC1 as a novel therapeutic target for the treatment of breast cancer.